(4S)-4-hydroxy-L-isoleucineWhat was measured
Measured, with no finding
183 endpoints
Show what was measuredHide what was measured
basal glycemia and basal insulinemia after 6-day subchronic dosing, and glucose tolerance on IVGTT (rats) and OGTT (dogs), in normal and non-insulin-dependent diabetic rats; glucose-induced insulin release from isolated islets
decreases
Not recorded as a finding: the paper never states the instrument the node requires
In non-insulin-dependent diabetic (NIDD) rats, a single intravenous administration of 4-OH-Ile (50 mg/kg) partially restored glucose-induced insulin response without affecting glucose tolerance; a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance.
PMID 10516120 · one of two readings recorded this
basal hyperglycemia
decreases
a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance
PMID 10516120 · one of two readings recorded this
basal insulinemia
decreases
a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance
PMID 10516120 · one of two readings recorded this
glucose-induced insulin release
increases
In vitro, 4-OH-Ile (200 microM) potentiated glucose (16.7 mM)-induced insulin release from NIDD rat-isolated islets.
PMID 10516120 · one of two readings recorded this
glucose-induced insulin response
increases
In non-insulin-dependent diabetic (NIDD) rats, a single intravenous administration of 4-OH-Ile (50 mg/kg) partially restored glucose-induced insulin response without affecting glucose tolerance
PMID 10516120 · one of two readings recorded this
glucose tolerance by intravenous glucose tolerance test in normal and NIDD rats and oral glucose tolerance test in normal dogs; basal glycemia and insulinemia; glucose-induced insulin release from isolated NIDD rat islets
Not recorded as a finding: a node exists but the paper states a different instrument or population
During IVGTT in normal rats or OGTT in normal dogs, 4-OH-Ile (18 mg/kg) improved glucose tolerance.
PMID 10516120 · one of two readings recorded this
glucose tolerance
increases
During IVGTT in normal rats or OGTT in normal dogs, 4-OH-Ile (18 mg/kg) improved glucose tolerance.
PMID 10516120 · one of two readings recorded this
glucose tolerance
increases
During IVGTT in normal rats or OGTT in normal dogs, 4-OH-Ile (18 mg/kg) improved glucose tolerance.
PMID 10516120 · one of two readings recorded this
glucose tolerance
increases
a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance
PMID 10516120 · one of two readings recorded this
glucose tolerance
no effect
In non-insulin-dependent diabetic (NIDD) rats, a single intravenous administration of 4-OH-Ile (50 mg/kg) partially restored glucose-induced insulin response without affecting glucose tolerance
PMID 10516120 · one of two readings recorded this
glucose tolerance
no effect
The lactonic form of 4-OH-Ile was ineffective in normal rats.
PMID 10516120 · one of two readings recorded this
hepatic glucose production
decreases
Euglycemic hyperinsulinemic clamp experiments revealed that ID-1101 can improve insulin resistance through an increase of peripheral glucose utilization rate in sucrose-lipid-fed rats and by decreasing hepatic glucose production in Zucker fa/fa rats.
PMID 15082420 · one of two readings recorded this
insulinemia after chronic treatment in type 2 diabetic rats and obese Zucker fa/fa rats
decreases
Not recorded as a finding: CAT:outcome/fasting-insulin requires a stated overnight fast; the abstract states none (instrument_not_stated)
Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats.
PMID 15082420 · one of two readings recorded this
insulinemia after chronic treatment in type 2 diabetic rats and Zucker fa/fa rats
decreases
Not recorded as a finding: fasting-insulin requires an overnight fast of at least 8 hours; the abstract states no fast or assay
Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats.
PMID 15082420 · one of two readings recorded this
insulinemia
decreases
Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats.
PMID 15082420 · one of two readings recorded this
peripheral glucose utilization rate
increases
Euglycemic hyperinsulinemic clamp experiments revealed that ID-1101 can improve insulin resistance through an increase of peripheral glucose utilization rate in sucrose-lipid-fed rats and by decreasing hepatic glucose production in Zucker fa/fa rats.
PMID 15082420 · one of two readings recorded this
PI 3-kinase activity (liver)
increases
Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats.
PMID 15082420 · one of two readings recorded this
PI 3-kinase activity (muscle)
increases
Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats.
PMID 15082420 · one of two readings recorded this
PI 3-kinase activity (muscle)
increases
Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats.
PMID 15082420 · one of two readings recorded this
progression of hyperinsulinemia
decreases
Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats.
PMID 15082420 · one of two readings recorded this
total cholesterol (TC)
decreases, p = 0.02
which significantly decreased the plasma triglyceride levels by 33% (P<0.002), total cholesterol (TC) by 22% (P<0.02), and free fatty acids by 14%, accompanied by an increase in HDL-C/TC ratio by 39% in the dyslipidemic hamster model
PMID 16246556 · one of two readings recorded this
free fatty acids
decreases
which significantly decreased the plasma triglyceride levels by 33% (P<0.002), total cholesterol (TC) by 22% (P<0.02), and free fatty acids by 14%, accompanied by an increase in HDL-C/TC ratio by 39% in the dyslipidemic hamster model
PMID 16246556 · one of two readings recorded this
HDL-C/TC ratio
increases
which significantly decreased the plasma triglyceride levels by 33% (P<0.002), total cholesterol (TC) by 22% (P<0.02), and free fatty acids by 14%, accompanied by an increase in HDL-C/TC ratio by 39% in the dyslipidemic hamster model
PMID 16246556 · one of two readings recorded this
plasma triglyceride levels
decreases, p = 0.002
which significantly decreased the plasma triglyceride levels by 33% (P<0.002), total cholesterol (TC) by 22% (P<0.02), and free fatty acids by 14%, accompanied by an increase in HDL-C/TC ratio by 39% in the dyslipidemic hamster model
PMID 16246556 · one of two readings recorded this
glucose
decreases, p = 0.01
Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.
PMID 18680121 · one of two readings recorded this
glucose
no effect
This prolonged exposure to 4-hydroxyisoleucine was well tolerated in control animals and did not alter levels of glucose or liver damage markers significantly.
PMID 18680121 · one of two readings recorded this
glucose
increases, p = 0.001
In fructose-fed rats, levels of glucose and liver damage marker aspartate transaminase were markedly (84% and 93%, respectively) and significantly elevated compared with controls (p < 0.001 for both).
PMID 18680121 · one of two readings recorded this
glucose
no effect
In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).
PMID 18680121 · one of two readings recorded this
alanine transaminase
decreases, p = 0.01
Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.
PMID 18680121 · one of two readings recorded this
alanine transaminase
increases
Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.
PMID 18680121 · one of two readings recorded this
aspartate transaminase
decreases, p = 0.01
Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.
PMID 18680121 · one of two readings recorded this
aspartate transaminase
increases, p = 0.001
In fructose-fed rats, levels of glucose and liver damage marker aspartate transaminase were markedly (84% and 93%, respectively) and significantly elevated compared with controls (p < 0.001 for both).
PMID 18680121 · one of two readings recorded this
blood glucose and liver damage markers in streptozotocin-diabetic rats
no effect
Not recorded as a finding: glucose fasting state not stated (CAT:outcome/fasting-blood-glucose requires an overnight fast); 'liver damage markers' do not name AST or ALT
In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).
PMID 18680121 · one of two readings recorded this
blood glucose, AST and ALT in fructose-fed rats
Not recorded as a finding: the sentence says markers were 'restored to near control values', no direction word per analyte; fasting not stated for fasting-blood-glucose; ALT and AST not named in the same sentence as the treatment effect
Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.
PMID 18680121 · one of two readings recorded this
glucose and liver damage markers in streptozotocin diabetic rats
no effect
Not recorded as a finding: 'did not affect' is stated, but fasting is not stated for fasting-blood-glucose, and the liver markers are not named, so aspartate-aminotransferase and alanine-aminotransferase cannot be mapped
In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).
PMID 18680121 · one of two readings recorded this
HDL-cholesterol
increases, p = 0.05
In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).
PMID 18680121 · one of two readings recorded this
liver damage markers
no effect
This prolonged exposure to 4-hydroxyisoleucine was well tolerated in control animals and did not alter levels of glucose or liver damage markers significantly.
PMID 18680121 · one of two readings recorded this
liver damage markers
no effect
In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).
PMID 18680121 · one of two readings recorded this
tolerability
This prolonged exposure to 4-hydroxyisoleucine was well tolerated in control animals and did not alter levels of glucose or liver damage markers significantly.
PMID 18680121 · one of two readings recorded this
triglycerides
decreases, p = 0.05
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
blood glucose and plasma insulin
decreases
Not recorded as a finding: fasting-blood-glucose and fasting-insulin require a stated fast; the abstract states none
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
blood glucose, plasma insulin and triglycerides
decreases
Not recorded as a finding: CAT:outcome/fasting-blood-glucose, fasting-insulin and serum-triglycerides each require a stated fast; the abstract states none (instrument_not_stated)
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
blood glucose
decreases, p = 0.05
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
low-density lipoprotein-cholesterol
decreases, p = 0.05
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
plasma high-density lipoprotein-cholesterol
increases, p = 0.05
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
plasma insulin
decreases, p = 0.05
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
plasma triglycerides
decreases
Not recorded as a finding: serum-triglycerides requires a sample after a stated fast; the abstract states none
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
total cholesterol
decreases, p = 0.05
4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.
PMID 20140804 · one of two readings recorded this
insulin level
decreases
Here we describe for the first time the anti-diabetic activity of 4HO-Ile in a model of type I diabetes, streptozotocin-treated rats, where levels of insulin are much reduced, by 65%, compared to normal animals.
PMID 22397995 · one of two readings recorded this
lipids (cholesterol, HDL, LDL, triglycerides) and uric acid
modulates
Moreover the high levels of lipids (cholesterol, HDL, LDL and triglycerides) and uric acid in the diabetic rats, could be restored to levels found in non-diabetic controls by the treatment with 4HO-Ile.
PMID 22397995 · one of two readings recorded this
plasma glucose, and plasma cholesterol, HDL, LDL, triglycerides and uric acid, in streptozotocin-induced type I diabetic rats
decreases
Not recorded as a finding: the paper never states the instrument the node requires
Treatment of diabetic rats with daily doses of 4HO-Ile at 50 mg/kg/day for four weeks could reduce plasma glucose in the diabetic group.
PMID 22397995 · one of two readings recorded this
plasma glucose in streptozotocin-induced type I diabetic rats; plasma cholesterol, HDL, LDL, triglycerides and uric acid
decreases
Not recorded as a finding: the paper never states the instrument the node requires
Treatment of diabetic rats with daily doses of 4HO-Ile at 50 mg/kg/day for four weeks could reduce plasma glucose in the diabetic group.
PMID 22397995 · one of two readings recorded this
plasma glucose
decreases
Treatment of diabetic rats with daily doses of 4HO-Ile at 50 mg/kg/day for four weeks could reduce plasma glucose in the diabetic group.
PMID 22397995 · one of two readings recorded this
AMPK and Akt expression and phosphorylation
increases
Interestingly, it also increased the AMPK and Akt expression along with their phosphorylated forms in the liver and muscle tissues of treated animals.
PMID 25454462 · one of two readings recorded this
blood lipid profile, glucose tolerance and insulin sensitivity in high-fructose-diet streptozotocin diabetic rats; glucose uptake and mitochondrial-biogenesis gene expression in L6 myotubes; AMPK and Akt expression and phosphorylation in liver and muscle
Not recorded as a finding: this platform holds no node for the endpoint
4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.
PMID 25454462 · one of two readings recorded this
blood lipid profile, glucose tolerance and insulin sensitivity in high-fructose-diet streptozotocin diabetic rats; glucose uptake and mitochondrial biogenesis gene expression (PGC-1alpha, PGC-1beta, CPT 1, CPT 2) in L6 myotubes, liver and muscle; AMPK and Akt expression and phosphorylation
Not recorded as a finding: the direction is carried only as a signed number
4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.
PMID 25454462 · one of two readings recorded this
blood lipid profile
modulates
4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.
PMID 25454462 · one of two readings recorded this
glucose tolerance
increases
4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.
PMID 25454462 · one of two readings recorded this
glucose uptake
increases
It has increased the glucose uptake in L6 myotubes in AMPK-dependent manner and upregulated the expression of genes (PGC-1α, PGC-1β, CPT 1 and CPT 2), which have role in mitochondrial biogenesis and energy metabolism in the liver, skeletal muscles as well as in L6 myotubes.
PMID 25454462 · one of two readings recorded this
insulin sensitivity
increases
4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.
PMID 25454462 · one of two readings recorded this
acetylcholine
increases, p = 0.001
Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg considerably and dose-dependently raised the levels of GABA (one-way ANOVA: F(5,25) = 3.337, p < 0.001), acetylcholine (one-way ANOVA: F(5,25) = 0.3535, p < 0.001), and serotonin (one-way ANOVA: F(5,25) = 1.245, p < 0.001) in the brain homogenate of MeHg-treated rats.
PMID 35745001 · one of two readings recorded this
nitrite
decreases, p = 0.001
Chronic treatment of three weeks with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lowered the levels of AchE(one-way ANOVA: F(5,25) = 2.460, p < 0.001), LDH (one-way ANOVA: F(5,25) = 4.095, p < 0.001), MDA (one-way ANOVA: F(5,25) = 1.081, p < 0.001), and nitrite (one-way ANOVA: F(5,25) = 2.286, p < 0.001).
PMID 35745001 · one of two readings recorded this
serotonin
increases, p = 0.001
Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg considerably and dose-dependently raised the levels of GABA (one-way ANOVA: F(5,25) = 3.337, p < 0.001), acetylcholine (one-way ANOVA: F(5,25) = 0.3535, p < 0.001), and serotonin (one-way ANOVA: F(5,25) = 1.245, p < 0.001) in the brain homogenate of MeHg-treated rats.
PMID 35745001 · one of two readings recorded this
acetylcholinesterase (AchE)
decreases, p = 0.001
Chronic treatment of three weeks with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lowered the levels of AchE(one-way ANOVA: F(5,25) = 2.460, p < 0.001), LDH (one-way ANOVA: F(5,25) = 4.095, p < 0.001), MDA (one-way ANOVA: F(5,25) = 1.081, p < 0.001), and nitrite (one-way ANOVA: F(5,25) = 2.286, p < 0.001).
PMID 35745001 · one of two readings recorded this
AchE, LDH, MDA and nitrite
increases
Long-term treatment withMeHg at a dose of 5 mg/kg for 21 dayson rats resulted in a considerable increase in AchE, LDH, MDA, and nitrite concentrations.
PMID 35745001 · one of two readings recorded this
apoptotic markers
modulates
Furthermore,4-HI100 mg/kg treatment was more effective than 4-HI50 mg/kg treatment in restoring the abnormal levels of apoptotic markers in rats.
PMID 35745001 · one of two readings recorded this
Bax (blood plasma)
decreases, p = 0.001
Likewise, continuous oral treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg remarkably decreased the level of the pro-apoptotic marker Bax in rat brain homogenate (one-way ANOVA: F(5,25) = 3.902, p < 0.001)and blood plasma (one-way ANOVA: F(5,25) = 1.642, p < 0.001)
PMID 35745001 · one of two readings recorded this
Bax (brain homogenate)
decreases, p = 0.001
Likewise, continuous oral treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg remarkably decreased the level of the pro-apoptotic marker Bax in rat brain homogenate (one-way ANOVA: F(5,25) = 3.902, p < 0.001)and blood plasma (one-way ANOVA: F(5,25) = 1.642, p < 0.001)
PMID 35745001 · one of two readings recorded this
Bcl-2 (blood plasma)
increases, p = 0.001
regular oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg for 21 days consecutively led to a considerable increase in the level of Bcl-2 protein in brain homogenate (one-way ANOVA: F(5,25) = 7.161, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 0.9438, p < 0.001) in the MeHg-treated rats
PMID 35745001 · one of two readings recorded this
Bcl-2 (brain homogenate)
increases, p = 0.001
regular oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg for 21 days consecutively led to a considerable increase in the level of Bcl-2 protein in brain homogenate (one-way ANOVA: F(5,25) = 7.161, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 0.9438, p < 0.001) in the MeHg-treated rats
PMID 35745001 · one of two readings recorded this
Bcl-2
decreases
In contrast, oral treatment with MeHg for 21 days led to a notable decline in anti-apoptotic Bcl-2 protein level in rat brain homogenate and blood plasma
PMID 35745001 · one of two readings recorded this
body weight (days 1 and 7)
no effect
On days 1and 7, there was no significant difference between the groups.
PMID 35745001 · one of two readings recorded this
body weight
increases, p = 0.001
Continuous oral administration of 4-HI50 mg/kg and 100 mg/kg significantly and dose-dependently improved the bodyweight when compared with MeHg-treated rats on the 14th, 21st, 28th, 35th and 42nd days of the experimental schedule (two-way ANOVA: F(30,180) = 187.8, p < 0.001)
PMID 35745001 · one of two readings recorded this
body weight
decreases
On days 14, 21, 28, 35 and 42, a gradual decline in bodyweight was found in rats treated with MeHg compared to normal control, vehicle control, and 4-HI100 perse treated groups.
PMID 35745001 · one of two readings recorded this
body weight
increases
On days 35 and 42, 4-HI100 mg/kg treated rats showed significant improvements in body weight restoration compared to the 4-HI50 mg/kg treatment rats.
PMID 35745001 · one of two readings recorded this
brain section pathology (cortical tissue loss, white matter degeneration)
decreases
Persistent treatment with 4-HI50 mg/kg and 4-HI100 mg/kg remarkably reversed these morphological alterations in brain sections and restored demyelination, measured by demyelination volume and MBP level assessment.
PMID 35745001 · one of two readings recorded this
brain section pathology (cortical tissue loss, white matter degeneration)
decreases
Among these, 4-HI100 mg/kg was more effective than 4-HI50 mg/kg in ameliorating the pathological abnormalities in brain sections.
PMID 35745001 · one of two readings recorded this
caspase-3 and Bax
increases
Long-term oral MeHg administration significantly increased pro-apoptotic markers like caspase-3 and Bax in rat brain homogenate and blood plasma.
PMID 35745001 · one of two readings recorded this
caspase-3 (blood plasma)
decreases, p = 0.001
Chronic oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg substantially reduced the level of caspase-3 in brain homogenate (one-way ANOVA: F(5,25) = 0.9588, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 0.5116, p < 0.001)
PMID 35745001 · one of two readings recorded this
caspase-3 (brain homogenate)
decreases, p = 0.001
Chronic oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg substantially reduced the level of caspase-3 in brain homogenate (one-way ANOVA: F(5,25) = 0.9588, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 0.5116, p < 0.001)
PMID 35745001 · one of two readings recorded this
cortical histopathology (oligodendrocytes, astrocytes)
unclear
With4-HI at a dose of 50 mg/kg, a gradual repair in the oligodendrocytes cells along with a slight decrease in the number of astrocytes was visible.
PMID 35745001 · one of two readings recorded this
cortical histopathology (oligodendrocytes, microglia, necrosis)
decreases
The dose of4-HI 100 mg/kg restored the shape of oligodendrocyte cells and decreased the microglial and necrosis areas.
PMID 35745001 · one of two readings recorded this
cortical histopathology (oligodendrocytes, microglia, necrosis)
increases
The methyl-mercury-treated group showed destruction of oligodendrocytes cells and the activation of microglia, and an increase in the area of necrosis.
PMID 35745001 · one of two readings recorded this
demyelination (myelin content destruction)
increases
Long-term oral administration of the neurotoxin MeHg for 21 days substantially induced the destruction of the myelin content compared to normal control, vehicle control, and 4-HI100- perse-treated animals.
PMID 35745001 · one of two readings recorded this
demyelination volume
decreases, p = 0.001
Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg considerably reduced the demyelination volume relative to MeHg-treated rats (one-way ANOVA: F(5,25) = 1.627, p < 0.001).
PMID 35745001 · one of two readings recorded this
demyelination volume
decreases
Consequently, 4-HI100 mg/kg showed a noticeable, dose-dependent improvement in myelin restoration compared to 4-HI50 mg/kg, as further evaluated by demyelination volume.
PMID 35745001 · one of two readings recorded this
escape latency time (ELT)
decreases, p = 0.001
Chronic treatment with 4-HI 50 mg/kg and 100 mg/kg resulted in a significant decrease in ELT compared to the MeHg-treated group (two-way ANOVA: F(10,60) = 1.891, p < 0.001).
PMID 35745001 · one of two readings recorded this
escape latency time (ELT)
increases
MeHg-treated rats showed a gradual increase in ELT compared to the normal control, vehicle control, and 4-HI100 perse groups.
PMID 35745001 · one of two readings recorded this
escape latency time (ELT)
decreases
Administration of 4-HI100 mg/kg led to a marked decline in ELT compared to the 4-HI 50 mg/kg treatment
PMID 35745001 · one of two readings recorded this
forelimb and hindlimb grip strength, grid force meter (Chatillon) in kgf
increases, F(15,90) = 119.6
Not recorded as a finding: CAT:outcome/handgrip-strength is hand-dynamometer grip in humans; rodent grid grip is a different instrument (endpoint_near_miss)
Prolonged administration of 4-HI 50 mg/kg and 100 mg/kg showed a remarkable improvement in grip strength force on days 22, 32 and 42 when compared to MeHg-treated rats (two-way ANOVA: F(15,90) = 119.6, p < 0.001).
PMID 35745001 · one of two readings recorded this
GABA, acetylcholine and serotonin
decreases
Oral administration of the toxin MeHg for 21 days consecutively resulted in a substantial decrease in GABA, acetylcholine, and serotonin levels.
PMID 35745001 · one of two readings recorded this
GABA
increases, p = 0.001
Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg considerably and dose-dependently raised the levels of GABA (one-way ANOVA: F(5,25) = 3.337, p < 0.001), acetylcholine (one-way ANOVA: F(5,25) = 0.3535, p < 0.001), and serotonin (one-way ANOVA: F(5,25) = 1.245, p < 0.001) in the brain homogenate of MeHg-treated rats.
PMID 35745001 · one of two readings recorded this
GLP-1 concentration (brain homogenate)
increases, p = 0.001
Prolonged 4-HI50 mg/kg and 100 mg/kg treatment led to a significant and dose-dependent increase in the GLP-1 concentration in brain homogenate (one-way ANOVA: F (5,25) = 2.009, p < 0.001) and CSF (one-way ANOVA: F(5,25) = 2.021, p < 0.001), respectively.
PMID 35745001 · one of two readings recorded this
GLP-1 concentration (CSF)
increases, p = 0.001
Prolonged 4-HI50 mg/kg and 100 mg/kg treatment led to a significant and dose-dependent increase in the GLP-1 concentration in brain homogenate (one-way ANOVA: F (5,25) = 2.009, p < 0.001) and CSF (one-way ANOVA: F(5,25) = 2.021, p < 0.001), respectively.
PMID 35745001 · one of two readings recorded this
GLP-1 level
decreases
MeHg-induced rats illustrated a remarkable decrease in the level of GLP-1 as compared to the normal control, vehicle control, and 4-HI100 perse treated groups.
PMID 35745001 · one of two readings recorded this
GLP-1 level
increases
Moreover, the 4-HI100 mg/kg dose was more efficient in restoring the level of GLP-1 in comparison with 4-HI50 mg/kg.
PMID 35745001 · one of two readings recorded this
glutamate
decreases, p = 0.001
However, oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg lowered the concentration of glutamate (one-way ANOVA: F(5,25) = 1.372, p < 0.001) in rat brain homogenate in contrast to the MeHg-treated group.
PMID 35745001 · one of two readings recorded this
glutamate
increases
In contrast, continuous oral MeHg intoxication led to a significant increase in the glutamate concentration in brain homogenate compared with normal control, vehicle control, and 4-HI100- perse-treated rats.
PMID 35745001 · one of two readings recorded this
grip strength force
increases, p = 0.001
Prolonged administration of 4-HI 50 mg/kg and 100 mg/kg showed a remarkable improvement in grip strength force on days 22, 32 and 42 when compared to MeHg-treated rats (two-way ANOVA: F(15,90) = 119.6, p < 0.001)
PMID 35745001 · one of two readings recorded this
grip strength force
decreases
The oral treatment with MeHg for 21 days consecutively led to a gradual decrease in grip strength force on days 22, 32 and 42 compared to normal control, vehicle control, and 4-HI100 perse groups.
PMID 35745001 · one of two readings recorded this
grip strength force
increases
Among these, 4-HI100 mg/kg was more effective than 4-HI 50 mg/kg in the restoration of grip strength on days 32 and 42.
PMID 35745001 · one of two readings recorded this
IGF-1 and GLP-1 in brain homogenate and CSF, ELISA
increases
Not recorded as a finding: CAT:outcome/serum-igf-1 requires serum; CAT:outcome/plasma-glp-1 requires postprandial plasma sampling; brain and CSF matrices differ (endpoint_near_miss)
Chronic oral administration of 4-HI at the doses of 50 mg/kg and 100 mg/kg remarkably increased the IGF-1 level in brain homogenate (one-way ANOVA: F(5, 25) = 5.595, p < 0.001) and CSF samples (one-way ANOVA: F(5,25) = 0.971, p < 0.001).
PMID 35745001 · both readings recorded this
IGF-1 level (brain homogenate)
increases, p = 0.001
Chronic oral administration of 4-HI at the doses of 50 mg/kg and 100 mg/kg remarkably increased the IGF-1 level in brain homogenate (one-way ANOVA: F(5, 25) = 5.595, p < 0.001) and CSF samples (one-way ANOVA: F(5,25) = 0.971, p < 0.001).
PMID 35745001 · one of two readings recorded this
IGF-1 level (CSF)
increases, p = 0.001
Chronic oral administration of 4-HI at the doses of 50 mg/kg and 100 mg/kg remarkably increased the IGF-1 level in brain homogenate (one-way ANOVA: F(5, 25) = 5.595, p < 0.001) and CSF samples (one-way ANOVA: F(5,25) = 0.971, p < 0.001).
PMID 35745001 · one of two readings recorded this
IGF-1 level
decreases
Oral administration of MeHg resulted in a significant decrease in the level of IGF-1 compared to the normal control, vehicle control, and 4-HI100 perse groups.
PMID 35745001 · one of two readings recorded this
IGF-1 level
increases
Moreover, 4-HI100 mg/kg was more efficient than 4-HI50 mg/kg in restoring the IGF-1 protein level in rat brain homogenate and CSF samples.
PMID 35745001 · one of two readings recorded this
IL-1β (blood plasma)
decreases, p = 0.001
Similarly, chronic oral treatment with 4-HI50 mg/kg and 4-HI100 mg/kg remarkably lowered the level of IL-1β in brain homogenate (one-way ANOVA: F(5,25) = 2.058, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 1.370, p < 0.001) as opposed to the MeHg-toxin-administered rats.
PMID 35745001 · one of two readings recorded this
IL-1β (brain homogenate)
decreases, p = 0.001
Similarly, chronic oral treatment with 4-HI50 mg/kg and 4-HI100 mg/kg remarkably lowered the level of IL-1β in brain homogenate (one-way ANOVA: F(5,25) = 2.058, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 1.370, p < 0.001) as opposed to the MeHg-toxin-administered rats.
PMID 35745001 · one of two readings recorded this
immobility time
decreases, p = 0.001
Long-term oral administration of 4-HI50 mg/kg and 4-HI100 mg/kg led to a considerable decline in the immobility time on days 28, 35 and 42 when compared to the MeHg-treated group (two-way ANOVA: F(15,90) = 87.32, p < 0.001)
PMID 35745001 · one of two readings recorded this
immobility time
increases
The MeHg-treated group showed depressive-like behaviour and a gradual increase in immobility time compared to normal control, vehicle control, and 4-HI100 perse treated rats.
PMID 35745001 · one of two readings recorded this
immobility time
decreases
Among these, 4-HI at a dose of 100 mg/kg was found to be more effective than 4-HI 50 mg/kg in reducing immobility time in rats on days 28, 35 and 42.
PMID 35745001 · one of two readings recorded this
lactate dehydrogenase (LDH)
decreases, p = 0.001
Chronic treatment of three weeks with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lowered the levels of AchE(one-way ANOVA: F(5,25) = 2.460, p < 0.001), LDH (one-way ANOVA: F(5,25) = 4.095, p < 0.001), MDA (one-way ANOVA: F(5,25) = 1.081, p < 0.001), and nitrite (one-way ANOVA: F(5,25) = 2.286, p < 0.001).
PMID 35745001 · one of two readings recorded this
locomotor activity and rearing
decreases
The MeHg-treated rats showed a progressive decline in the number of boxes crossed on days 11, 21, 31 and 41, and a considerable decrease in the number of rearings
PMID 35745001 · one of two readings recorded this
locomotor activity and rearing
increases
On days 31 and 41, it was observed that 4-HI100 mg/kg considerably enhanced locomotion and improved the rearing scores when compared to the 4-HI 50 mg/kg treatment group
PMID 35745001 · one of two readings recorded this
locomotor activity (boxes crossed)
increases, p = 0.001
Consequently, the regular administration of 4-HI 50 mg/kg and 100 mg/kg significantly enhanced the locomotor activity (two-way ANOVA: F(20,120) = 35.71, p < 0.001)
PMID 35745001 · one of two readings recorded this
malondialdehyde (MDA)
decreases, p = 0.001
Chronic treatment of three weeks with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lowered the levels of AchE(one-way ANOVA: F(5,25) = 2.460, p < 0.001), LDH (one-way ANOVA: F(5,25) = 4.095, p < 0.001), MDA (one-way ANOVA: F(5,25) = 1.081, p < 0.001), and nitrite (one-way ANOVA: F(5,25) = 2.286, p < 0.001).
PMID 35745001 · one of two readings recorded this
myelin basic protein (brain homogenate)
increases, p = 0.001
In comparison to the MeHg-treated group, long-term treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg enhanced MBP level in rat brain homogenate (one-way ANOVA: F(5,25) = 0.7205, p < 0.001) but lowered the MBP level in CSF (one-way ANOVA: F(5,25) = 0.5460, p < 0.001).
PMID 35745001 · one of two readings recorded this
myelin basic protein (CSF)
decreases, p = 0.001
In comparison to the MeHg-treated group, long-term treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg enhanced MBP level in rat brain homogenate (one-way ANOVA: F(5,25) = 0.7205, p < 0.001) but lowered the MBP level in CSF (one-way ANOVA: F(5,25) = 0.5460, p < 0.001).
PMID 35745001 · one of two readings recorded this
myelin basic protein (lower in brain, higher in CSF)
modulates
MBP levels were considerably lower in brain homogenate and higher in CSF samples in theMeHg-toxin-treated compared to the normal control, vehicle control, and 4-HI100 perse groups.
PMID 35745001 · one of two readings recorded this
myelin basic protein restoration
modulates
It was also found that 4-HI100 mg/kg administration effectively restored the altered MBP levels compared to 4-HI50 mg/kg administration
PMID 35745001 · one of two readings recorded this
neuroinflammatory cytokines (TNF-α, IL-1β)
decreases
Meanwhile, 4-HI100 mg/kg treatment showed a marked improvement in reducing the level of these neuroinflammatory cytokines compared to the 4-HI50 mg/kg dose.
PMID 35745001 · one of two readings recorded this
neurotransmitter imbalance
modulates
Among these, the most significant improvements were observed in 4-HI100-mg/kg-treated rats versus the 4-HI50-mg/kg-treated rats in restoring neurotransmitter imbalance.
PMID 35745001 · one of two readings recorded this
oxidative stress markers and antioxidants
modulates
Compared to 4-HI50 mg/kg, the 4-HI100 mg/kg treatment significantly reduced oxidative stress markers while restoring antioxidant levels in a dose-dependent manner.
PMID 35745001 · one of two readings recorded this
rearing score (anxiety)
increases, p = 0.001
and restored the level of anxiety (rearing score)(two-way ANOVA: F(20,120) = 16.16, p < 0.001) as compared to MeHg-treated rats
PMID 35745001 · one of two readings recorded this
reduced glutathione (GSH)
increases, p = 0.001
However, 4-HI50 mg/kg and 100 mg/kg remarkably restored the anti-oxidant defence system by considerably increasing the levels of reduced glutathione (one-way ANOVA: F(5,25) = 1.226, p < 0.001) and SOD (one-way ANOVA: F(5,25) = 0.8858, p < 0.001) when compared with MeHg-treated rats.
PMID 35745001 · one of two readings recorded this
relative brain-body weight ratio
no effect
The normal and vehicle control groups showed no significant difference in the relative brain–body weight ratio compared to 4-HI perse treated rats.
PMID 35745001 · one of two readings recorded this
relative brain-body weight ratio
increases, p = 0.001
Long-term oral administration of 4-HI at the doses of 50 mg/kg and 100 mg/kg substantially enhanced the relative brain–body weight ratio compared to the MeHg-treated rats (one-way ANOVA: F(5,25) = 0.632, p < 0.001)
PMID 35745001 · one of two readings recorded this
relative brain-body weight ratio
decreases
Moreover, compared to the normal control, vehicle control, and 4-HI100 perse groups, MeHg-induced rats demonstrated a steady decline in relative brain–body weight ratio.
PMID 35745001 · one of two readings recorded this
relative brain-body weight ratio
increases
Compared to the 4-HI 50 mg/kg treated group, 4-HI100 mg/kg demonstrated a considerable increase in relative brain–body weight ratio.
PMID 35745001 · one of two readings recorded this
SOD and GSH
decreases
In contrast, oral MeHg administration led to a substantial decline in antioxidants like SOD and GSH compared to normal control, vehicle control, and 4-HI100- perse-treated groups.
PMID 35745001 · one of two readings recorded this
superoxide dismutase (SOD)
increases, p = 0.001
However, 4-HI50 mg/kg and 100 mg/kg remarkably restored the anti-oxidant defence system by considerably increasing the levels of reduced glutathione (one-way ANOVA: F(5,25) = 1.226, p < 0.001) and SOD (one-way ANOVA: F(5,25) = 0.8858, p < 0.001) when compared with MeHg-treated rats.
PMID 35745001 · one of two readings recorded this
time spent in target quadrant (TSTQ)
increases, p = 0.001
Long-term oral treatment with 4-HI 50 mg/kg and 100 mg/kg comparatively increased the TSTQ compared to theMeHg-treated group (one-way ANOVA: F(5,25) = 1.967, p < 0.001).
PMID 35745001 · one of two readings recorded this
time spent in target quadrant (TSTQ)
decreases
MeHg-induced rats demonstrated a more substantial decrease in time spent in the target zone than in the normal control, vehicle control, and 4-HI100 perse groups.
PMID 35745001 · one of two readings recorded this
time spent in target quadrant (TSTQ)
increases
Relatively, 4-HI100 mg/kg showed a significant rise in TSTQ compared to 4-HI-50 mg/kg-treated rats.
PMID 35745001 · one of two readings recorded this
TNF-α (blood plasma)
decreases, p = 0.001
Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lessened the TNF-α level in rat brain homogenate (one-way ANOVA: F(5,25) = 3.181, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 1.682, p < 0.001), respectively.
PMID 35745001 · one of two readings recorded this
TNF-α (brain homogenate)
decreases, p = 0.001
Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lessened the TNF-α level in rat brain homogenate (one-way ANOVA: F(5,25) = 3.181, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 1.682, p < 0.001), respectively.
PMID 35745001 · one of two readings recorded this
whole-brain morphology and brain weight
increases
Continuous oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg was observed to be efficient in restoring the alterations in brain weight and effectively reducing cortical degeneration.
PMID 35745001 · one of two readings recorded this
whole-brain morphology and brain weight
decreases
MeHg-treated rat brains showed shrinkage in size and reduced overall brain mass compared to normal control, vehicle control, and 4-HI- perse-treated groups.
PMID 35745001 · one of two readings recorded this
whole-brain morphology and brain weight
increases
However, 4-HI100-mg/kg-treated rats showed significant improvements in whole-brain morphology compared to the 4-HI50 mg/kg treated rats.
PMID 35745001 · one of two readings recorded this
abnormal sperm morphology
no effect
However, sperm morphology in all three mice groups was less defective, with no significant differences.
PMID 40917356 · one of two readings recorded this
blood glucose during insulin tolerance test (ITT)
decreases
In addition, the insulin tolerance test (ITT) revealed that unlike mice with obesity that were highly resistant to insulin injection, mice treated with 4-HIL had a significantly lower blood glucose concentration, similar to that in ND mice.
PMID 40917356 · one of two readings recorded this
blood glucose during pyruvate tolerance test (PTT)
unclear
The pyruvate tolerance test (PTT) results showed a significant enhancement in blood glucose concentration in 4-HIL treated mice compared to that in mice with obesity.
PMID 40917356 · one of two readings recorded this
body weight
decreases
Consistent with previous reports, we observed that 4-HIL treatment significantly reduced the body weight of mice in the HFD group compared to HFD mice without treatment.
PMID 40917356 · one of two readings recorded this
days to pregnancy and pups per litter (mating trial)
increases
We noticed that 4-HIL treated mice were able to impregnate females in a shorter period and produced a significantly higher number of pups per litter than HFD group males.
PMID 40917356 · one of two readings recorded this
differentially expressed genes (up/down) in testis
modulates
In addition, 281 genes were upregulated and 188 genes were downregulated in the testes of 4-HIL mice.
PMID 40917356 · one of two readings recorded this
differentially expressed genes (up/down) in testis
modulates
Among these genes, 206 were upregulated and 282 were downregulated in the testes of the mice with obesity.
PMID 40917356 · one of two readings recorded this
epididymal adipose tissue weight
decreases
Not recorded as a finding: CAT:outcome/fat-mass is whole-body adipose mass; a single fat-pad weight is a different construct (endpoint_near_miss)
Lastly, we found reduced epididymal adipose weight in 4-HIL mice compared with that in mice with obesity.
PMID 40917356 · one of two readings recorded this
epididymal adipose weight
decreases
Not recorded as a finding: no node; fat-mass is whole-body adipose mass
Lastly, we found reduced epididymal adipose weight in 4-HIL mice compared with that in mice with obesity.
PMID 40917356 · one of two readings recorded this
epididymal adipose weight
decreases
Lastly, we found reduced epididymal adipose weight in 4-HIL mice compared with that in mice with obesity.
PMID 40917356 · one of two readings recorded this
epididymal sperm count and concentration, CASA (TOX IVOS)
increases
Not recorded as a finding: sperm-concentration requires ejaculate semen analysis per WHO methodology; this is epididymal sperm diluted in culture medium
Based on the CASA results, 4-HIL treated mice had a significantly higher sperm count and concentration than those in the HFD group.
PMID 40917356 · one of two readings recorded this
epididymal sperm count and concentration, computer-assisted sperm analysis (TOX IVOS)
increases
Not recorded as a finding: CAT:outcome/sperm-concentration requires ejaculate semen analysis per WHO methodology; this is epididymal sperm in mice (endpoint_near_miss)
Based on the CASA results, 4-HIL treated mice had a significantly higher sperm count and concentration than those in the HFD group.
PMID 40917356 · one of two readings recorded this
epididymal sperm count and concentration
increases
Based on the CASA results, 4-HIL treated mice had a significantly higher sperm count and concentration than those in the HFD group.
PMID 40917356 · one of two readings recorded this
fasting blood glucose before treatment (HFD vs ND)
increases
Prior to treatment, HFD mice (mice with obesity) had a significantly higher blood glucose concentration than ND mice (Supplementary Figures S1B–D)
PMID 40917356 · one of two readings recorded this
genes identified by testis mRNA sequencing
A total of 25,702 genes were identified.
PMID 40917356 · one of two readings recorded this
germinal epithelium congestion of seminiferous tubule lumen
decreases
however, 4-HIL treated mice had less crowded germinal epithelia, leading to visible boundaries in the lumen of the seminiferous tubules
PMID 40917356 · one of two readings recorded this
glucose tolerance (GTT)
increases
After six weeks of treatment, mice with obesity treated with 4-HIL showed improved glucose tolerance compared to HFD mice.
PMID 40917356 · one of two readings recorded this
glucose tolerance, intraperitoneal glucose tolerance test (2 g/kg), glucometer
Not recorded as a finding: no node for an intraperitoneal GTT in mice; postprandial-glucose-auc requires an oral load or mixed drink
After six weeks of treatment, mice with obesity treated with 4-HIL showed improved glucose tolerance compared to HFD mice.
PMID 40917356 · one of two readings recorded this
IL-6 and TNFα concentration
decreases
In addition, inflammatory markers, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα), were assessed, and their serum and testis concentrations were found to be reduced in 4-HIL treated mice compared to those in HFD mice (Supplementary Figures S2C, D)
PMID 40917356 · one of two readings recorded this
IVF 4-cell embryos (4-HIL vs normal diet)
decreases
However, the percentage of 4-cell embryos produced from the sperms of 4-HIL treated mice was significantly lower than that of 4-cell embryos from normal diet-fed mice.
PMID 40917356 · one of two readings recorded this
IVF 4-cell embryos (HFD vs 4-HIL)
increases
In addition, there was a significantly reduced number of 4-cell embryos obtained from mice with obesity (HFD group) compared to that of 4-HIL treated mice.
PMID 40917356 · one of two readings recorded this
IVF embryos progressing to blastocyst
increases
Approximately 30% of the embryos from mice in the HFD group progressed to the blastocyst stage, which was lower than the 55% and 61% of blastocysts derived from 4-HIL treated and normal control mice, respectively.
PMID 40917356 · one of two readings recorded this
IVF zygote number (fertilization rate)
no effect
We observed that the fertilization rates among the mice groups were high, with no significant difference in the number of zygotes produced.
PMID 40917356 · one of two readings recorded this
MDA concentration
decreases
We found a decrease and significant reduction of MDA concentration in the serum and testis respectively of 4-HIL-treated mice compared to those in the HFD group (Supplementary Figure S2A)
PMID 40917356 · one of two readings recorded this
pups per litter and days to pregnancy in mating trials; IVF embryo development
increases
Not recorded as a finding: no node
We noticed that 4-HIL treated mice were able to impregnate females in a shorter period and produced a significantly higher number of pups per litter than HFD group males.
PMID 40917356 · one of two readings recorded this
serum and testis MDA and SOD, ELISA
decreases
Not recorded as a finding: malondialdehyde-circulating requires TBARS or HPLC, this was ELISA; serum decrease not stated as significant; SOD described only as 'optimized'
We found a decrease and significant reduction of MDA concentration in the serum and testis respectively of 4-HIL-treated mice compared to those in the HFD group (Supplementary Figure S2A).
PMID 40917356 · one of two readings recorded this
serum FSH, LH and testosterone direction
unclear
FSH levels were higher in 4-HIL-treated mice than in HFD mice, and LH levels within 4-HIL mice were similar to those of ND mice, and testosterone levels were lower in HFD mice than in 4-HIL-treated mice.
PMID 40917356 · one of two readings recorded this
serum LDL-c, HDL-c and triglycerides, Nanjing Jiancheng kits
Not recorded as a finding: the sentence says the lipids were 'remarkably optimized' with no direction per analyte and no fast stated; ldl-cholesterol, hdl-cholesterol and serum-triglycerides cannot take a direction from it
However, after treatment, the same lipid parameters were found to be remarkably optimized in 4-HIL treated mice compared to those without treatment.
PMID 40917356 · both readings recorded this
serum lipids before treatment (LDL-c, TG high; HDL-c low)
modulates
Furthermore, before the mice with obesity were treated with 4-HIL, they exhibited high serum concentrations of low-density lipoprotein cholesterol (LDL-c) and triglycerides (TG) and low serum concentrations of high-density lipoprotein cholesterol (HDL-c) (Supplementary Figure S1E)
PMID 40917356 · one of two readings recorded this
serum lipids (LDL-c, TG, HDL-c)
modulates
However, after treatment, the same lipid parameters were found to be remarkably optimized in 4-HIL treated mice compared to those without treatment.
PMID 40917356 · one of two readings recorded this
serum testosterone, FSH and LH, ELISA
Not recorded as a finding: not significant and the sentence states no two-sided absence per hormone; total-testosterone cannot take a direction
4-HIL treatment improved spermatogenic hormone levels, but no statistically significant differences were observed.
PMID 40917356 · both readings recorded this
SOD level
increases
Similarly, in 4-HIL-treated mice, SOD levels were optimized, with a restoration of SOD concentration in the serum and testis (Supplementary Figure S2B)
PMID 40917356 · one of two readings recorded this
spem1 and spata24 relative normalized expression (qPCR)
increases
The qPCR results revealed significantly higher relative normalized expression levels of spem1 and spata24 in the testes of mice treated with 4-HIL than in HFD group.
PMID 40917356 · one of two readings recorded this
spermatogenesis genes dazl, insl6, spem1, spata24 (RNA-seq)
increases
with dazl, insl6, spem1, and spata24 upregulated in the testes of mice treated with 4-HIL and downregulated in the testes of mice with obesity (Supplementary Figure S3A)
PMID 40917356 · one of two readings recorded this
spermatogenic hormones (FSH, LH, testosterone)
no effect
4-HIL treatment improved spermatogenic hormone levels, but no statistically significant differences were observed.
PMID 40917356 · one of two readings recorded this
testicular apoptotic cells
no effect
Furthermore, in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays, we observed a higher number of apoptotic cells in HFD group mice than in the 4-HIL treatment group; however, no statistically significant difference was established.
PMID 40917356 · one of two readings recorded this
testicular lipid deposition
decreases
Additionally, Oil Red O staining revealed intense lipid deposition in the peritubular spaces and interstitium of the testes of HFD group mice, as opposed to the testes of 4-HIL treated mice.
PMID 40917356 · one of two readings recorded this
testicular spem1 and spata24 mRNA expression, qPCR
increases
Not recorded as a finding: gene expression is not an outcome node or a protein-activity mechanism
The qPCR results revealed significantly higher relative normalized expression levels of spem1 and spata24 in the testes of mice treated with 4-HIL than in HFD group.
PMID 40917356 · both readings recorded this
testis weight
no effect
We first examined the testes of mice from all three (3) groups after 16 weeks of feeding and treatment and found no significant difference in testis weight among the groups.
PMID 40917356 · one of two readings recorded this
IGF-1, GLP-1 and cytokine mRNA expression
modulates
Additionally, qRT-PCR showed that 4-HI administration modulated mRNA expression of IGF-1, GLP-1, and cytokines.
PMID 41187648 · one of two readings recorded this
myelin repair, neuroinflammation, hematological profile and brain pathology
modulates
Histopathological analysis revealed enhanced myelin repair, reduced neuroinflammation, normalized hematological profiles, and mitigated pathological alterations in various brain regions.
PMID 41187648 · one of two readings recorded this
neurobehavioral performance (neuromuscular coordination, locomotion, cognition), pro-inflammatory cytokines, apoptotic markers, neurotransmitter levels, hematological indices, histopathological myelin repair, and IGF-1/GLP-1 mRNA by qRT-PCR in ethidium-bromide-demyelinated rats
Not recorded as a finding: this platform holds no node for the endpoint
The study found that 4-HI treatment improved neuromuscular coordination, locomotion, and cognitive function.
PMID 41187648 · one of two readings recorded this
neuromuscular coordination, locomotion and cognitive function
increases
The study found that 4-HI treatment improved neuromuscular coordination, locomotion, and cognitive function.
PMID 41187648 · one of two readings recorded this
pro-inflammatory cytokines, pro-apoptotic markers and neurotransmitter imbalance
decreases
It reduced pro-inflammatory cytokines, pro-apoptotic markers, and restored neurotransmitter imbalances.
PMID 41187648 · one of two readings recorded this